Roche Tecentriq combined with Avastin's combination therapy achieves positive results in the treatment of HCC3 trials

recently, Roche announced positive results in a combination of pD-L1 antibody Tecentriq (atezolizumab, atlizumab) combined with Avastin (bevacizumab, bevazumab) to treat patients who have not previously received systemic treatment for non-reprecentable hepatocellular carcinoma (HCC) stage 3trial(http://IMbrave150data show that the Tecentriq/Avastin combination reduced the risk of death by 42 percent compared to Sorafini and 41 percent less risk of disease progression or deathThis immunocombination therapy is the first clinical study in 10 years to confirm that it is superior to existing standard therapiesAbout Tecentr
entrentritec has been approved in the United States, the European Union and other countries, can be used alone, can also be used in combination with targeted therapy or chemotherapy, for various forms of non-small cell and small cell lung cancer, certain types of metastatic urethra icy cancer, and PD-L1-positive metastatic triple-negative breast cancerAbout Avastin
Avastin is an antibody against vascular endothelial growth factor (VEGF), which inhibits tumor growth and diffusion by directly binding VEGF to the bloodsupply of(http://Tecentriq plus Avastin's combination therapy may enhance the immune system's potential to fight widespread cancersIn July 2018, the U.SFDA(http://granted Tecentriq/Avastin combination therapy breakthrough therapy to identify advanced or metastatic HCC for first-line therapy 　　A combination of inhibitors targeting the PD-1/PD-L1 pathway and inhibitors of targeted VEGF signaling pathways have been approved by the FDA four times in recent years , the Keytruda/Inlyta combination of MSD and The Bavencio/Inlyta combination of Merck KGaA/Pfizer of Germany were approved for first-line treatment of renal cell carcinoma The Keytruda/Lenvima combination of Eisai was approved for treatment of specific endometrial cancer patients Roche's Tecentriq/Avastin/Chemotherapy triple therapy was also approved for treatment of non-small cell lung cancer The tecentriq/Avastin combination therapy was successful in a first-line trial of liver cancer, demonstrating the good prospects for this combination strategy